shutterstock_1425740486_ii_studio

II Studio / Shutterstock.com

24 October 2019Big PharmaSaman Javed

Brazil accuses Gilead over 1,421.5% price hike of hep C drug

The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Brazil rules 10-year patent term ‘unconstitutional’

11 May 2021 Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.

More on this story

article

Brazil rules 10-year patent term ‘unconstitutional’

11 May 2021 Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.

More on this story

article

Brazil rules 10-year patent term ‘unconstitutional’

11 May 2021 Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB